A5029537053- COVID-19 Impact on Reproduction
- Reproductive System and Pregnancy
- Pregnancy and Medication Impact
- Neonatal Respiratory Health Research
- Gestational Diabetes Research and Management
- Infant Development and Preterm Care
- Vaccine Coverage and Hesitancy
- Congenital Diaphragmatic Hernia Studies
- Birth, Development, and Health
- SARS-CoV-2 and COVID-19 Research
Sheba Medical Center
2019-2024
Tel Aviv University
2019-2024
United States Nuclear Regulatory Commission
2021
To determine the immunogenicity and reactogenicity of Pfizer/BioNTech BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine among pregnant women compared with non-pregnant women, to evaluate obstetric outcome following vaccination.
(1) Background: The adverse-effect profile and short-term obstetric neonatal outcomes among pregnant women who were vaccinated with the BNT162b2 vaccine at any stage of pregnancy do not indicate safety concerns. is effective in generating a humoral immune response women. (2) Objective: To determine vaccine-induced immunity adverse events associated third (booster) dose compared to first second (3) Study design: A prospective cohort study tertiary referral center comparing by...
The objective of the study was to compare maternal and neonatal humoral immune responses among different groups women, namely those vaccinated by BNT162b2 vaccine, not vaccinated, COVID-19-recovered parturient women at time delivery. This is a prospective cohort pregnant divided into four groups: Group A “Recovered”—recovered vaccinated. B “Second Vaccination”—first second doses only. C “Third Vaccination”—third dose. D “No Third Vaccination”—women eligible for third dose vaccine but did...